Gemtuzumab ozogamicin 0.1 mg
Products billed under this code include Mylotarg.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Mylotarg.
Payment limit per 0.1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Mylotarg | Pfizer Inc | 00008-4510-01 | 45 | $11,131.65 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $247.37 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted September 17, 2026 |
| 3Q26 | $247.37 | +$7.205 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted September 15, 2026 |
| 2Q26 | $240.165 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted September 15, 2026 |
| 1Q26 | $240.165 | +$3.549 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted September 15, 2026 |
| 4Q25 | $236.616 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted September 8, 2026 |
| 3Q25 | $236.616 | +$3.497 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted March 10, 2026 |
| 2Q25 | $233.119 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted March 10, 2026 |
| 1Q25 | $233.119 | +$3.445 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted December 19, 2025 |
| 4Q24 | $229.674 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 11, 2025 |
| 3Q24 | $229.674 | +$3.394 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 11, 2025 |
| 2Q24 | $226.28 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted March 11, 2025 |
| 1Q24 | $226.28 | +$4.437 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted December 19, 2024 |
| 4Q23 | $221.843 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted October 10, 2024 |
| 3Q23 | $221.843 | +$4.35 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 5, 2024 |
| 2Q23 | $217.493 | +$0.061 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted February 23, 2024 |
| 1Q23 | $217.432 | +$3.153 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted December 6, 2023 |
| 4Q22 | $214.279 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 22, 2023 |
| 3Q22 | $214.279 | +$3.167 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 9, 2023 |
| 2Q22 | $211.112 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted December 14, 2022 |
| 1Q22 | $211.112 | +$3.12 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 8, 2022 |
| 4Q21 | $207.992 | $0.00 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 2, 2022 |
| 3Q21 | $207.992 | +$2.652 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted June 2, 2022 |
| 2Q21 | $205.34 | −$0.022 | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted March 1, 2022 |
| 1Q21 | $205.362 | – | 0.1 MG | Gemtuzumab ozogamicin 0.1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.